General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Stocks Churn as Traders Waver on US Rates Outlook: Markets Wrap | news.google.com • |
Microsoft Stock Outlook: Is MSFT a Millionaire-Maker AI Play to Make? | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-15 | 2024-03 | -0.88 | -1.55 | -0.67 | -76.14% |
2024-02-14 | 2023-12 | -1 | -0.8 | 0.2 | 20.00% |
2023-12-22 | 2023-09 | -1 | -1 | N/A | N/A |
2023-08-14 | 2023-06 | -0.8 | -1.6 | -0.8 | -100.00% |
2023-05-15 | 2023-03 | -1.2 | -0.6 | 0.6 | 50.00% |
2023-02-14 | 2022-12 | -0.8 | -1.6 | -0.8 | -100.00% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-30 | Chardan Capital | Downgrade | Buy | Neutral |
2023-08-30 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2023-08-29 | Brookline Capital | Downgrade | Buy | Hold |
2023-08-29 | Cantor Fitzgerald | Downgrade | Overweight | Neutral |
2023-08-29 | BTIG | Downgrade | Buy | Neutral |
2023-08-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-04-19 | DAGNON TERRY | Chief Operating Officer | 653.06K | Sale |
2024-03-06 | EVANSON JEFF | Officer | 808.46K | Purchase |
2024-03-27 | HADDADIN YEZAN MUNTHER | Director | 5.05K | Purchase |
2022-10-04 | HILZINGER KURT J | Director | 473.12K | Purchase |
2021-04-19 | KENYON LAWRENCE A. | Chief Executive Officer | 18.93K | Purchase |
2022-10-06 | SUKHTIAN FAISAL GHIATH | Director | 68.00K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 9.22M | 16.04M | 3.54% |
2023-06-29 | Vanguard Group Inc | 6.15M | 10.70M | 2.36% |
2023-06-29 | State Street Corporation | 2.75M | 4.79M | 1.06% |
2023-06-29 | Geode Capital Management, LLC | 2.72M | 4.73M | 1.05% |
2023-06-29 | Northern Trust Corporation | 1.26M | 2.18M | 0.48% |
2023-06-29 | Nuveen Asset Management, LLC | 598.96K | 1.04M | 0.23% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.61M | 6.28M | 1.39% |
2023-08-30 | iShares Russell 2000 ETF | 3.58M | 815.24K | 1.37% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.45M | 2.52M | 0.56% |
2023-07-30 | Fidelity Small Cap Index Fund | 1.38M | 2.38M | 0.53% |
2023-08-30 | iShares Russell 2000 Growth ETF | 1.27M | 289.29K | 0.49% |
2023-05-30 | Fidelity Extended Market Index Fund | 519.75K | 779.62K | 0.20% |
Split | Date |
---|---|
1 : 20 | 2024-03-14 |
1 : 8 | 2019-03-18 |
Frank Chance the short answer is “YES”!!! Now go you go figure out why. I don’t have time to educate a clown with a bad attitude.
Frank Chance do you have anything… anything at all that would back EmA not getting approved? No, I didn’t think so.
Think of how big the market is growing and is going to be one in 10 adults over the age of 80 will get age related macular degeneration. The market is already at 19.5 billion dollars and growing every year as baby boomers age. A branded product less expensive than bio similars. How much more of the market will out look take? The molecule already has half the market off label with exclusivity it will take all of that plus of the growing market.
John, sounds like a day you will come to regret. There is NO factual rational reason to sell OTLK today. If you are going to invest on your emotions perhaps you should have someone else manage your money. Best of luck
Alex Tarani, don’t listen to the blundering wizard or Frank chance it’s a 19 1/2 billion dollar market this molecule commands half of that market off label. This indication will get exclusivity work it backwards with the amount of shares outstanding, and you can see the money remaining.
Frank Chance, The ROI with the additional cash far exceeds an additional partners take. Keep in mind that the total market pie has increase by 3 billion to 19.5 billion dollars annually. Don’t you worry your little head …. We are all going to make money holding OTLK
Frank Chance,
Don’t you ever get tired of making g predictions from the back seat. This is old news and no you don’t get credit for stating an obvious well known fact andyou have the gall to call us clowns.
Frank Chance, if you knew what the EMA outcome was going to be… you could not legally say. You are psycho babbling again you should go take your medicine.
Frank Chance, you forgot your take your medicine this morning. You are psycho babbling again.
Andrew Day,
Two things to add to your value calculation. First the market pie has increased by 3 billion more dollars from 2020. Second, the warrants are a backstop of the finance. It’s not a great deal, but we may not need much of it, especially with two approvals in hand dust the company will not be diluted that much in value.
Frank Chance, quit saying things you don't know. Everyone here show know that you don't do any homework and have a history of saying really uneducated BS
Frank Chance it is deceiving not to tell them that EMA approval is expected in February you forgot to add that to your pricing. It is scummy not to disclose the whole truth. There was always going to be some dissolution for working capital to finish this project. That is old news!!! Today's price is a meaningless number because it doesn't reflect the value once approved with ready made market. Until EMA decision in February, any movement in the price is based on nothing.
Frank Chance, didn't be an A$$. Why would it be? Price change needs a catalyst. Look for a $1 plus before the end of the month.
Frank Chance, try again that is the wrong answer. Clearly you are confused
Waldo III, you have it backwards EMA comes sometime in February FDA doesn’t come until the end of the year but I do agree. It will go up over a dollar within the next 30 days.
Frank Chance, can you tell us what the stock price is with $6 billion in revenue and $40 million shares after 30/1 reverse split. Blow the dust off your old finance text book and look it up. That will be the answer to all your questions.
Frank Chance let us know when you actually have news. You are getting to be an old joke “Captain Obvious”.
Javi, please examine EU being a long shot. Based on my research OTLK is very prepared to obtain EMA approval in Feb. I know there are no guarantees but I don’t see any red flags or stumbling block for this approval. It looks like a slam dunk….. what am I missing?
Frank chance what a bunch of BS. Do you have a clue how uninformed you are. Please try doing some homework before you speak. Every investor here knew we would need more money to go to market. Quit trying to make news of it. Your surprise is your ignorance. If you knew anything about the pharmaceutical approvals you would not be so bold about not getting approval. Again you didn’t do your homework work. The FDA comparator study required has already been done by NEI years ago. EMA is open to supporting studies. There are no known red flags for EMA approval. You need to learn how to calculate company values. There is a reason smarter people (insiders and institutions) are willing to invest more money in and NOT sell. Close your mouth and open your ears… try to learn something. Smarter people than you are at work here.
I don’t want to put the horse before the cart. Do keep this in mind. There are two more eye diseases that are using this molecule off label. They also have billion dollar markets. I know Norse 7 is a study for safety of a device (new indication) but look at the arms for guidance. It’s ok to pessimistic about dilution, but don’t forget to be optimistic of the label expansion how are you?